Opendata, web and dolomites

OXIFLOW SIGNED

Next Generation Flow Diverter for the Treatment of Intracranial Aneurysms Delivering Improved Patient Outcomes and Healthcare Cost Savings

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OXIFLOW project word cloud

Explore the words cloud of the OXIFLOW project. It provides you a very rough idea of what is the project "OXIFLOW" about.

shape    overcoming    apposition    away    clipping    surgical    treatment    thereby    expectations    flow    unruptured    safety    nitinol    inherent    endovascular    restrict    period    options    subarachnoid    haemorrhage    business    causes    tortuous    radial    ethical    risk    uniform    approvals    aneurysm    40    origami    lower    clinical    small    complete    transfer    made    generating    invasive    avoidable    vessel    addressable    weak    poor    minimally    poorer    risky    02m    sah    ing    fim    severe    extension    cumulative    performance    suffer    live    rupture    procedure    guidewire    inferior    regulatory    diverters    failed    patient    manufacture    resolution    innovative    first    vessels    whom    revenues    citizens    divert    coiling    blood    freeze    man    porosity    excellent    market    utilises    73    each    die    fd    coning    56m    material    disabilities    ias    healing    natural    delivering    whilst    mesh    cheaper    expensive    51    central    pilot    memory    intracranial    ia    463m    forces    principles    oe    fds    limitations    entirely    oxiflow    reporting    device    optimum   

Project "OXIFLOW" data sheet

The following table provides information about the project.

Coordinator
OXFORD ENDOVASCULAR LIMITED 

Organization address
address: 9400, GARSINGTON ROAD, OXFORD
city: OXFORD
postcode: OX4 2HN
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 4˙232˙828 €
 EC max contribution 2˙962˙979 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OXFORD ENDOVASCULAR LIMITED UK (OXFORD) coordinator 2˙962˙979.00

Map

 Project objective

Each year ~51,000 EU citizens suffer a subarachnoid haemorrhage (SAH) resulting from the rupture of an intracranial aneurysm (IA), of whom 40% will die and 40% will suffer severe disabilities. However, SAH’s are entirely avoidable through treatment of ‘at risk’ unruptured IAs.

Existing treatment options include: surgical clipping, an invasive, risky and expensive procedure but delivering excellent long-term resolution; and endovascular coiling, a cheaper and lower risk minimally invasive procedure but delivering poorer long-term resolution. Flow diverters (FDs) are an emerging endovascular device that divert blood flow away from the aneurysm thereby enabling natural healing. Whilst offering the potential of excellent long-term resolution at low risk and cost, existing FDs have failed to live up to expectations, reporting performance inferior to coiling. Limitations of existing FD’s are inherent to their mesh design that causes weak and non-uniform radial forces resulting in poor vessel apposition, variable porosity and device coning. Existing delivery systems also restrict use due to extension of the central guidewire during delivery.

OxiFlow is a unique FD design based on origami principles and made from a shape memory Nitinol material. The innovative design enables optimum and uniform radial forces thereby overcoming the limitations of existing FDs. Furthermore, OxiFlow utilises a novel delivery system enabling complete user control of the central guidewire extension and thus use in small and tortuous vessels.

OXIFLOW will evaluate safety and performance of the OxiFlow device through a 10-patient First-in-Man (FIM) study. Project activities include: device design freeze, transfer to pilot scale manufacture, pre-clinical testing; regulatory and ethical approvals; and FIM study implementation.

The addressable EU & US market for OxiFlow is estimated at €463M. OE target €40.02M business growth over a 5-year period generating €73.56M cumulative revenues.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OXIFLOW" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OXIFLOW" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

TuneFork (2018)

Mobile technology that brings personalized audio into your life

Read More  

PestiSi (2019)

Cost effective solution against insects in long-term grain storage by natural diatomaceous earth

Read More